This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

8 Mar 2011

NovaBay Starts Urinary Tract Infection Trial

NovaBay Pharmaceuticals, Inc. provided an update on its Phase 2 clinical trial for the use of its NVC-422 to prevent urinary catheter blockage and encrustation (UCBE).

NovaBay Pharmaceuticals has launched a Phase II trial of a compound to prevent urinary catheter blockage and encrustation (UCBE), a major factor behind urinary tract infections. The trial is expected to be completed in the third quarter of 2011 with results available in the fourth quarter.


The multi-centre, randomised, double-blind proof-of-concept trial will compare the use of a catheter irrigation solution containing the compound, NVC-422, against the use of a saline irrigation, the commonly used option for UCBE treatment.


The study will involve subjects with a history of chronic episodes of UCBE.


The trial design is a crossover study in which

Related News